Government will decide on vaccination of children, adolescents on 'scientific rationale', supply situation: Covid Task Force Chief
Zydus Cadila's indigenously developed needle-free COVID-19 vaccine ZyCoV-D is set to become the first vaccine that will be available in India for those in the age group of 12-18 years.
The Ahmedabad-based company had projected the vaccine as a painless vaccine that has to be administered in three doses.
Sources added that a few more rounds of negotiations are likely this week before a government procurement price, as well as price of the vaccine in private hospitals can be fixed.
The Centre is hopeful of a positive outcome from talks with Zydus Cadila, says State Health Minister Dr K Sudhakar while 250 PHCs get upgraded in Karnataka.
ZyCoV-D has to be differently priced as apart from being a three-dose vaccine, there is a needle-free jet injector used for administering the vaccine.
Kids Covid vaccine: Centre hopeful of positive outcome from talks with Zydus Cadila, says Karnataka Health Minister
He said he also discussed with the Bharat Biotech chief about the status of the nasal vaccine.
AhmEdabad-based Zydus Cadila’s three-dose Covid-19 vaccine is likely to be included in the national vaccination drive from Saturday, according to Union Health Secretary Rajesh Bhushan.
As far as the price at which it will be procured is concerned, Union Health Secretary Rajesh Bhushan told a press conference that the government is in talks with the manufacturer.
The drug will be manufactured at the Zydus group's formulation manufacturing facility at the special economic zone, Ahmedabad, the drug firm noted.
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
The permission granted by DCGI in August was for a three-dose schedule, which was tested for efficacy in the Phase 3 clinical trials.
So far only Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has received Emergency Use Authorisation to be administered in the age group of under 18 years in the country.
Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday.
Dr N K Arora said it is estimated that there are around 12 crore adolescents in the age group of 12-18 years in India and less than 1 per cent of them may have comorbidities.
Vaccination for adolescents and kids with serious comorbidities, however, are likely to start in October when sufficient doses of ZyCoV D is available.